FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Cheniere Energy

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

Our 12-month target of $304, cut $1, reflects relative valuation and DCF models. We apply an 11.5x multiple of enterprise value to projected 2027 EBITDA, above Cheniere's historical forward average, which we see as reasonable given the very real concern over interrupted natural gas cargoes out of Qatar, a key competitor of Cheniere's. On this basis, we estimate a value of $280 per share. Meanwhile, our DCF model, using medium-term FCF growth of 6% per year, terminal growth of 2.5%, and discounted at a WACC of 6.8%, yields a value of $334 per share. We raise our 2026 EPS estimate by $4.42 to $18.90 and our 2027 EPS estimate by $1.90 to $16.19. The Strait of Hormuz remains a massive energy bottleneck, and physical damage to Qatar's LNG export capabilities creates a window of opportunity for Cheniere. Cheniere has limited spot exposure in 2026, but this may encourage more long-term deals with Cheniere if it is seen as a more reliable supplier.

Related Articles

Research

Research Alert: CFRA Lowers Rating On Shares Of Boston Scientific Corporation To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $56 from $100 on 14.4x our 2027 EPS estimate, a discount to BSX's five-year historical forward P/E average. We reduce our 2026 EPS view to $3.32 from $3.40 as we lower our quarterly estimates on margin concerns. We also lower our 2027 EPS forecast to $3.90 from $4.04. While we see healthy growth in procedures and diagnostics in the long run, we are uncertain about the near-term evolution of elective surgeries due to softening demand and weakening consumer sentiment in the U.S., which hit an all-time low in May amid a complex macroeconomic environment. At the same time, we continue to see tariffs as a considerable pressure point on the cost side, as many companies in the industry have global supply chains, while competition is intensifying between BSX, Medtronic, J&J, and Abbott, in our view. Amid these challenges coupled with margin pressures stemming from rising raw material costs and supply chain challenges, we prefer to remain on the sidelines and lower our view to Hold from Buy.

$BSX
Research

Research Alert: CFRA Downgrades Rating On Shares Of Palo Alto Networks Inc. To Buy From Strong Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We up our target to $280 from $193, on a P/E of 68x our FY 27 EPS estimate. We keep our FY 26 EPS view at $3.70 but lift our FY 27 EPS forecast to $4.12 from $4.01. PANW continues to strengthen its portfolio. We highlight the increased focus on agentic capabilities, such as the acquisition of Koi (completed in April) for its Agentic Endpoint Security tools, and its recent launch of Idira, a next-gen Identity Security platform that enhances Privilege Access Management with agentic functionality. PANW also announced its intent to acquire Portkey to enable users to centrally manage AI Agents. With Agentic adoption scaling rapidly, we believe CISOs have to allocate more budget to agentic security, an area where most are lacking in solutions. Additionally, Idira's launch represents the GTM execution of its CyberArk acquisition, and we expect cross-platform selling to start ramping. That said, shares have rallied substantially the last month (+48%) and we see a less attractive risk-reward at current multiples.

$PANW
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Dexcom

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month price target remains $67, 26x our 2026 EPS estimate (raised by $0.09 to $2.58; 2027 estimate raised by $0.06 to $3.05), below DXCM's one-year historical forward average of 33.5x and well below long-term term historical averages to reflect stronger competition within the continuous glucose monitoring space and uncertain insurance coverage and rebate dynamics, in our view. On May 14, DXCM announced a collaboration with activist investment firm Elliott Management, which holds a meaningful equity stake in DCXM (undisclosed amount), based on DXCM's recent press release. Among other potential changes, DXCM is making changes to the composition of its Board of Directors. The company also revealed some details about the upcoming G8 device, which is 50% smaller than the G7 and offers superior performance in terms of speed and real-time sensing capabilities. The G8 is expected to launch toward the end of 2027 or beginning of 2028.

$DXCM